Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...

James Manning / PA Images / Getty Images After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of ...

Are you a print subscriber? Activate your account. By Garett Sloane - 3 min 8 sec ago By Ewan Larkin - 8 min 31 sec ago By ...

JPMorgan placed shares of Novo Nordisk (NVO) on “Positive Catalyst Watch” ahead of the CagriSema REDEFINE 1 obesity data. The ...

Novo Nordisk, the company behind Ozempic and Wegovy, is now Europe's largest company as global demand for its drugs have soared. But the Danish pharmaceutical company's origins were motivated by ...

This week, 60 Minutes traveled to Denmark to report on Novo Nordisk, the pharmaceutical company that's behind the popular drugs Wegovy and Ozempic. Novo Nordisk's success with these drugs has led ...

Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...

Good day, and thank you for standing by. Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that today's conference is being ...